To cite this article: Paffen E, Medina P, de Visser MCH, van Wijngaarden A, Zorio E, Estellé s A, Rosendaal FR, Españ a F, Bertina RM, Doggen CJM.The )589C>T polymorphism in the interleukin-4 gene (IL-4) is associated with a reduced risk of myocardial infarction in young individuals. J Thromb Haemost 2008; 6: 1633-8.Summary. Background: Inflammatory reactions contribute to the development of arterial disease. We investigated the role of interleukin-4 (IL-4) in the development of myocardial infarction (MI) by genotyping patients with MI and control subjects for the )589C>T (rs2243250) single nucleotide polymorphism (SNP), which tags a functional haplotype of IL-4. Methods and results: Study of Myocardial Infarctions Leiden (SMILE) included 560 men with a first MI and 646 control subjects. The Valencia study included 305 patients with MI at £52 years (men and women) and 310 control subjects. In SMILE no clear overall association with the )589C>T genotype was found [odds ratio (OR) 0.84; 95% CI 0.37-1.95 for )589TT and 0.82; 95% CI 0.62-1.07 for )589CT compared with )589CC]. In patients younger than 50 years, carriership of one or two )589T alleles was associated with a reduced risk of MI (OR 0.57: 95% CI 0.34-0.95). This result was replicated in the Valencia study, where carriers of one or two )589T alleles had a reduced risk of MI , with a strong protective effect of the )598T allele in homozygous )589T (OR 0.33: 95% CI 0.10-1.05). In the control subjects of the Valencia study, the )589T allele was associated with reduced levels of F1+2. Conclusion: Our data indicate that the IL-4 haplotype tagged by the )589T allele reduces the risk of MI in young individuals.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.